NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.3 Sex hormones and hormone antagonists in malignant disease > 8.3.4 Hormone antagonists > 8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists > Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA387

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA387

1.1 Abiraterone in combination with prednisone or prednisolone is recommended, within its marketing authorisation, as an option for treating metastatic hormone-relapsed prostate cancer:

  • in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated

  • only when the company provides abiraterone in accordance with the commercial access arrangement as agreed with NHS England.

https://www.nice.org.uk/guidance/ta387

Site by Devopa
© Copyright 2019 NHS. All rights reserved.